drugset / Trial / NCT03067753

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

NCT03067753

Phase 2 Unknown 28 enrolled Zhejiang Cancer Hospital
RandomizedSequentialOpen-labelTreatment

Summary

Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis

Timeline

Start
2016-12
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 1 g Intravenous
Subject Monosialoganglioside Ganglioside Unknown 100 mg
Comparator Prednisolone Other / unclassified Oral